ATR and melanoma: Clinical trials, such as those involving ceralasertib, have demonstrated encouraging results, particularly in melanomas resistant to PD-1 inhibitors, suggesting the value of ATR inhibitors in enhancing immune responses and improving outcomes in melanoma treatment [155,156].